详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4

54| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Oncology, Affiliated Hospital of Chengdu University, Chengdu 610081, People’s Republic of China. [2]Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China. [3]Department of respiratory and critical care medicine, Guangyuan Central Hospital, Guangyuan City, Sichuan Province, 628000, China. [4]Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China.

出处：

DOI：

ISSN：

关键词： Thyroid gland carcinoma LncRNA PANDAR MiR-637 KLK4 Progression

摘要：

Thyroid gland carcinoma (TC) originates from follicular or parafollicular thyroid cells and is one of the most common endocrine organ malignancies. To explore the molecular mechanism by which long-chain non-coding RNAs regulate the growth and metastasis of thyroid gland carcinoma, in this study we focused on long non-coding RNAs (lncRNAs) that have been reported to be involved in tumorigenesis. We identified Promoter Region of CDKN 1A antisense DNA damage-activated RNA (PANDAR), which was positively correlated with thyroid gland carcinoma risk. PANDAR could promote thyroid gland carcinoma cell proliferation and metastasis. PANDAR negatively correlated with miR-637, and miR-637 overexpression suppressed thyroid gland carcinoma progression, which could be reversed by PANDAR. MiR-637 could target Kallikrein-related peptidases 4 (KLK4) to inhibit its expression, which was high in thyroid gland carcinoma. KLK4 inhibited cell progression in thyroid gland carcinoma cells. Knockdown of PANDAR expression inhibited cancer progression in nude mice. Overall, PANDAR can suppress miR-637 and induce KLK4 to regulate invasion and migration in thyroid gland carcinoma. Additionally, we identified miR-637 as a target of PANDAR in thyroid gland carcinoma, and PANDAR can be used as a novel therapeutic target for the treatment of thyroid gland carcinoma.

基金：

基金编号： 2019YJ0652

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.3 最新[2023版] 3.4 最新五年平均 4.478 出版当年[2021版] 4.505 出版当年五年平均 4.207 出版前一年[2020版] 3.9 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Oncology, Affiliated Hospital of Chengdu University, Chengdu 610081, People’s Republic of China.

通讯作者：

通讯机构： [2]Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China. [4]Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China. [*1]Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China. [*2]Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Partial preservation of the normal thyroid gland based on tumor diameter may be possible in small medullary thyroid carcinoma: a two-center 15-year retrospective study [2]AUF1-induced circular RNA hsa_circ_0010467 promotes platinum resistance of ovarian cancer through miR-637/LIF/STAT3 axis [3]甲状腺髓样癌的诊治进展 [4]体素内不相干运动双指数模型的技术现况 [5]中性粒细胞的异质性和多潜能性在肿瘤进展中的作用 [6]Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC [7]Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study [8]Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound [9]PTBP1通过调控FGFR2的可变剪接促进肝癌的发展 [10]The Role of CD276 in Cancers.